Precision Medicine · uk
Bringing Genomic Reports Into Time for Treatment Decisions: Pediatric Cancer Sequencing Cut to Three Days
A study involving 54 children reduced the average wait for whole-genome reports from 42 days to three days. Earlier access to a tumor’s molecular clues could help guide drug selection and risk stratification, but larger studies are still needed to determine whether it improves survival or reduces care costs.
When a child is suspected of having cancer, the medical team often has to decide on the next step within days, while genomic reports may take weeks. A study published in *Nature Communications* on October 6 sought to bring these two timelines closer together: a rapid whole-genome sequencing workflow reduced the average reporting time from 42 days to three days, giving molecular information a chance to inform initial treatment decisions.
The study enrolled 54 children with suspected or confirmed cancer between 2023 and 2025. Of these, 35 underwent prospective evaluation, while stored samples from another 19 were analyzed retrospectively. The three days refers to the average time from when all samples required for analysis were available to the issuance of a report suitable for clinical interpretation. It does not mean that every child can receive a diagnosis within three days of their visit.
The shorter wait came from integrating sample processing, sequencing, and data analysis. Some blood cancer samples could enter the rapid workflow directly as blood or bone marrow lysates, eliminating several preprocessing steps. A project summary from the UK Health Research Authority shows that this feasibility study, sponsored by Cambridge University Hospitals NHS Foundation Trust, was designed from the outset to identify risk earlier and support treatment decisions. That document records the study plan, rather than treatment efficacy results.
Beyond speed, the study also compared variant detection. Of the 155 clinically actionable variants identified through various methods across the entire study cohort, the rapid workflow detected 147, or approximately 95%; routine whole-genome sequencing detected 138, or approximately 89%. These are detection proportions at the variant level. They cannot be interpreted as cancer diagnostic accuracy, nor do they indicate that the rapid workflow can replace all other tests.
Among the 35 prospective cases, clinical teams recorded benefits to care decisions for 17 children, including earlier risk stratification, access to targeted treatment, or avoidance of unnecessary tests and treatment escalation. These observations give concrete meaning to faster reporting in patient care, but they remain physician-assessed benefits to decision-making and cannot directly be taken to imply improved survival.
A medRxiv preprint of the same study was released on September 2, 2025. An early summary included in PREreview reported three days versus 37 days, and improved care for 18 of the 35 prospective cases; the final journal version reported 42 days and 17 children. These are different versions of the same study. Reporting should use the final results and should not mix in preliminary data.
This study remains a small, single-center feasibility evaluation without randomization. The rapid workflow also missed some clinically significant variants, so speed must be weighed alongside testing quality. Multicenter studies are needed next to confirm whether different hospitals can reproduce the results and whether earlier access to information truly improves patient outcomes and is cost-effective, before its role in routine pediatric cancer care can be determined.